h1

000852074 001__ 852074
000852074 005__ 20230512150827.0
000852074 0247_ $$2HSB$$aeva473244
000852074 0247_ $$2ISSN$$a0007-1188
000852074 0247_ $$2ISSN$$a0366-0826
000852074 0247_ $$2ISSN$$a1476-5381
000852074 0247_ $$2ISSN$$a2056-8177
000852074 0247_ $$2SCOPUS$$aSCOPUS:2-s2.0-85112739023
000852074 0247_ $$2WOS$$aWOS:000685876500001
000852074 0247_ $$2doi$$a10.1111/bph.15588
000852074 0247_ $$2pmid$$apmid:34409595
000852074 0247_ $$2datacite_doi$$a10.18154/RWTH-CONV-249162
000852074 037__ $$aRWTH-CONV-249162
000852074 041__ $$aEnglish
000852074 1001_ $$0P:(DE-82)IDM05726$$aWeiskirchen, Ralf$$b0$$eCorresponding author$$urwth
000852074 245__ $$aPhysalin B attenuates liver fibrosis via suppressing LAP2 alpha-HDAC1 mediated deacetylation of glioma-associated oncogene 1 and hepatic stellate cell activation$$honline, print
000852074 260__ $$aMalden, MA$$bWiley$$c2021
000852074 3367_ $$00$$2EndNote$$aJournal Article
000852074 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal
000852074 3367_ $$2BibTeX$$aARTICLE
000852074 3367_ $$2DRIVER$$aarticle
000852074 3367_ $$2DataCite$$aOutput Types/Journal article
000852074 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000852074 591__ $$aGermany
000852074 773__ $$0PERI:(DE-600)2029728-2$$a10.1111/bph.15588$$n20$$p4045-4047$$tBritish journal of pharmacology$$v178$$x2056-8177
000852074 8564_ $$uhttps://publications.rwth-aachen.de/record/852074/files/852074.pdf$$yOpenAccess
000852074 909CO $$ooai:publications.rwth-aachen.de:852074$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000852074 9101_ $$0I:(DE-588b)36225-6$$6P:(DE-82)IDM05726$$aRWTH Aachen$$b0$$kRWTH
000852074 9141_ $$y2021
000852074 9151_ $$0StatID:(DE-HGF)0031$$2StatID$$aPeer reviewed article$$x0
000852074 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-02
000852074 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-02
000852074 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-02-02
000852074 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-02
000852074 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-02-02
000852074 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J PHARMACOL : 2019$$d2021-02-02
000852074 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-02-02$$wger
000852074 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-02
000852074 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000852074 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000852074 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-02-02
000852074 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J PHARMACOL : 2019$$d2021-02-02
000852074 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-02-02
000852074 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-02
000852074 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-02
000852074 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-02-02
000852074 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-02
000852074 9201_ $$0I:(DE-82)526000-3_20140620$$k526000-3$$lInstitut und Lehrstuhl für Molekulare Pathobiochemie, experimentelle Gentherapie und klinische Chemie$$x0
000852074 961__ $$z2022-10-27
000852074 970__ $$aeva473244
000852074 980__ $$aI:(DE-82)526000-3_20140620
000852074 980__ $$aUNRESTRICTED
000852074 980__ $$aVDB
000852074 980__ $$ajournal
000852074 9801_ $$aFullTexts